Aura drops headcount by 20%, rejigs C-suite amid R&D refocusing
Aura drops headcount by 20%, rejigs C-suite amid R&D refocusing
Aura Biosciences
Targeted oncology company developing therapies for ocular and urologic oncology indications using a novel virus-like drug conjugate (VDC) platform.
Company Info
Sector:Oncology / Ophthalmology
Headquarters:Cambridge, Massachusetts, USA
Founded:2009
Website:www.aurabiosciences.com/
Upcoming Milestones & Key Dates
2026 Q4
Clinical Data
Choroidal melanoma Phase 2/3 data update
2027
Regulatory
Potential NDA filing for choroidal melanoma
Clinical Development Pipeline
AU-011
Target: HPV E6/E7 surface proteinAU-011
Target: HPV E6/E7 surface proteinRecent News
Leadership Team
Elisabet de los Pinos
Chief Executive Officer
Chris Primiano
Chief Business Officer
David Fanger
Chief Scientific Officer